Study Finds Lung Inflammation Worse in E-Cigarette Users Than Smokers
By SOCIETY OF NUCLEAR MEDICINE AND
MOLECULAR IMAGING
Vaping refers to the use of electronic cigarettes, or e-cigarettes, which are devices that heat a liquid into an aerosol that is then inhaled.
Vaping has become increasingly popular as an alternative to smoking traditional cigarettes, but there is growing concern about the potential health risks associated with vaping.
A recent study, published in The Journal of Nuclear Medicine, has found that individuals who use electronic cigarettes, or e-cigarettes, experience greater lung inflammation compared to cigarette smokers and non-smokers.
This is the first study to demonstrate that using e-cigarettes to
vape e-liquids results in a unique inflammatory response in the lungs that is
separate from the response seen in cigarette smoking.
In recent years, the use of e-cigarettes has seen a significant surge, particularly among young adults and adolescents.
Despite the widespread
belief that e-cigarettes are a safer alternative to traditional cigarettes,
they have been found to trigger pulmonary inflammation and increase the
likelihood of lung disease. Moreover, their long-term safety has not been
thoroughly evaluated, leaving many questions about their impact on health
unanswered.
This is the first PET study to use a novel radiotracer, 18F-NOS, to compare lung inflammation between cigarette and e-cigarette users in vivo. Although PET imaging with 18F-FDG has been used in the past to investigate inflammation in smokers and vapers, its conclusions were limited.
“iNOS is an enzyme that is overexpressed in e-cigarette users and cigarette smokers and is associated with acute and chronic inflammatory diseases,” said Reagan Wetherill, Ph.D., the study’s lead author and faculty member at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia.
“This makes it a relevant target for molecular imaging of lung inflammation and
inflammatory lung disease.”
Summary of the pilot study and preliminary PET imaging findings. Credit: R Wetherill, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Study participants were divided into three age- and sex-matched
groups: five e-cigarette users, five cigarette smokers, and five
never-smoked/vaped controls. 18F-NOS PET was performed to quantify and compare
lung inflammation.
E-cigarette users showed greater pulmonary inflammation than
cigarette smokers and never-smoked/vaped controls. A positive association
between pulmonary and peripheral measures of inflammation was also found,
suggesting that e-cigarette use may increase pulmonary inflammation.
“Having these findings provides patients with additional evidence
about the potentially harmful effects of e-cigarette use on the lungs,” says
Wetherill. “Our work advances what is currently known about the impacts of
e-cigarette use on respiratory health and provides a better understanding of
harm and harm reduction associated with e-cigarette use relative to cigarette
smoking.”
Senior author and Perelman School of Medicine Department of Radiology faculty member Jacob Dubroff, MD, Ph.D., sees a growing role for using molecular imaging to understand the effects of electronic cigarettes.
He
notes, “These findings suggest molecular imaging may be uniquely poised to
detect and measure the potential pathophysiologic harms associated with
electronic cigarettes, which have been touted as a safer vehicle for nicotine
compared to traditional combustible cigarettes.”
Reference: “Molecular imaging of pulmonary inflammation in
electronic and combustible cigarette users: a pilot study” by Reagan R.
Wetherill, Robert K. Doot, Anthony J. Young, Hsiaoju Lee, Erin K. Schubert,
Corinde E. Wiers, Frank T. Leone, Robert H. Mach, Henry R. Kranzler and Jacob
G. Dubroff, January 2023, Journal of Nuclear Medicine.
DOI:
10.2967/jnumed.122.264529
The study was funded by the National Heart, Lung and Brain
Institute, the National Institute on Drug Abuse, and the National Center for
Advancing Translational Sciences (NCATS).